

Parkinson Disease: An Overview of a Complex Neurological Disorder

Yuki Tanaka*

Department of Neurology, Osaka University, Japan

Introduction

Parkinson disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Characterized by its impact on motor control, Parkinson disease primarily manifests through tremors, rigidity, and bradykinesia (slowness of movement). Though it primarily affects older adults, the disease can begin in middle age or even earlier. Understanding Parkinson disease involves exploring its symptoms, underlying mechanisms, and current treatment options. The symptoms of Parkinson disease develop gradually and can vary from person to person. Early signs often include subtle changes in movement, such as a slight tremor in one hand, stiffness in the limbs, or difficulty with balance and coordination. As the disease progresses, these symptoms typically become more pronounced and can lead to significant impairments in daily activities.

Description

A characteristic shaking or trembling of the hands, arms, legs, or face that occurs when the muscles are at rest. Slowness of movement that can affect tasks like walking, writing, or buttoning a shirt. Stiffness and inflexibility of the muscles, which can cause discomfort and limit movement. Difficulty maintaining balance, leading to an increased risk of falls. Non-motor symptoms are also common and may include cognitive changes, mood disorders such as depression, sleep disturbances, and autonomic dysfunction. These non-motor symptoms can significantly impact the quality of life and complicate the management of the disease. Diagnosis of Parkinson disease is primarily clinical, based on the presence of characteristic motor symptoms and the exclusion of other conditions. There are no definitive tests for Parkinson; however, imaging techniques like MRI and PET scans can help rule out other disorders and assess brain function. Parkinson disease is caused by the progressive degeneration of dopamine-producing neurons in a part of the brain called the substantia nigra. Dopamine is a neurotransmitter that plays a crucial role in coordinating smooth and controlled muscle movements. As these neurons die, dopamine levels decrease, leading to the motor symptoms characteristic of Parkinson disease. The exact cause of neuronal degeneration in Parkinson disease remains unclear. However, research suggests a combination of genetic, environmental, and lifestyle factors may contribute to the onset of the disease. Some genetic mutations have been linked to familial forms of Parkinson, while environmental factors such as exposure to toxins have been proposed as potential contributors. While there is no cure for Parkinson disease, various treatments can help manage symptoms and improve quality of life. Treatment strategies generally include, the primary treatment involves medications that increase dopamine levels or mimic

dopamine's effects. Levodopa, often combined with carbidopa, is the most effective medication for controlling motor symptoms. Physical therapy plays a crucial role in managing Parkinson disease by helping patients maintain mobility, flexibility, and strength. Exercise programs tailored to individual needs can help address motor symptoms and improve overall physical function. For advanced cases or when medications are no longer effective, surgical options such as Deep Brain Stimulation (DBS) may be considered. DBS involves implanting electrodes in specific brain regions to regulate abnormal neural activity and alleviate symptoms. Supportive care, including occupational therapy, speech therapy, and psychological support, can help patients cope with the various challenges of Parkinson disease [1-4].

Conclusion

In conclusion, Parkinson disease is a complex and challenging condition that affects motor function and quality of life. While current treatments can manage symptoms and improve daily living, ongoing research and innovation are essential for developing more effective therapies and ultimately finding a cure. Awareness and understanding of Parkinson disease are crucial for supporting affected individuals and advancing the quest for better treatment.

Acknowledgement

None.

Conflict of Interest

Authors declare that they have no conflict of interest.

References

1. Khosla, N and Valdez R. "A Compilation of National Plans, Policies and Government Actions for Rare Diseases In 23 Countries". *Intractable Rare Dis Res* 7(2018):213–222.
2. Hoffman-Andrews, L. "The Known Unknown: The Challenges of Genetic Variants of Uncertain Significance in Clinical Practice." *J Law Biosci* 4(2018):648–657.
3. Palade, G. "Intracellular Aspects of the Process of Protein Synthesis." *Science* 189(1975):347–358.
4. Montpetit, B and Conibear E. "Identification of the Novel TRAPP Associated Protein Tca17." *Traffic* 10(2009):713–723.

How to cite this article: Tanaka Y. "Parkinson Disease: An Overview of a Complex Neurological Disorder" *J Neurol Disord.* 12 (2024):614.

*Address for Correspondence: Yuki Tanaka, Department of Neurology, Osaka University, Japan, Email: tanakayuki@111.jp

Copyright: © 2024 Yuki Tanaka. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 31-July-2024, Manuscript No. jnd-24-147228; **Editor assigned:** 02-August-2024, PreQC No. P-147228 (PQ); **Reviewed:** 16-August-2024; QC No. Q-147228; **Revised:** 21-August-2024; Manuscript No. R-147228 (R); **Published:** 28-August-2024, DOI: 10.4172/2329-6895.12.4.614